Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
492
datasets available to search
ShareScore release 0.9.0
Dataset results
492 results for “EGFR mutations;”
RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)
ClinicalTrials.gov study NCT03259009. IPD Sharing: Not stated. Countries: 0. Publications: 12.
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
ClinicalTrials.gov study NCT01646125. IPD Sharing: Not stated. Countries: 12. Publications: 0.
Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC
ClinicalTrials.gov study NCT03008109. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
ClinicalTrials.gov study NCT02208843. IPD Sharing: Not stated. Countries: 7. Publications: 0.
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib
ClinicalTrials.gov study NCT04640870. IPD Sharing: NO. Countries: 0. Publications: 24.
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Pac
ClinicalTrials.gov study NCT06048315. IPD Sharing: YES. Countries: 0. Publications: 8.
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03831932. IPD Sharing: YES. Countries: 1. Publications: 0.
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
ClinicalTrials.gov study NCT02454933. IPD Sharing: YES. Countries: 3. Publications: 0.
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
ClinicalTrials.gov study NCT00577707. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
ClinicalTrials.gov study NCT02349633. IPD Sharing: YES. Countries: 4. Publications: 0.
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
ClinicalTrials.gov study NCT00567359. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
ClinicalTrials.gov study NCT02318368. IPD Sharing: NO. Countries: 7. Publications: 0.
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
ClinicalTrials.gov study NCT02450591. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
ClinicalTrials.gov study NCT01520870. IPD Sharing: Not stated. Countries: 1. Publications: 0.
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
ClinicalTrials.gov study NCT02418234. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04206787. IPD Sharing: YES. Countries: 1. Publications: 0.
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
ClinicalTrials.gov study NCT02044380. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
ClinicalTrials.gov study NCT02514174. IPD Sharing: Not stated. Countries: 1. Publications: 0.
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutat
ClinicalTrials.gov study NCT01853826. IPD Sharing: YES. Countries: 11. Publications: 0.
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
ClinicalTrials.gov study NCT04512430. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.